Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06204250
Other study ID # GenSci074-102
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 27, 2024
Est. completion date December 17, 2024

Study information

Verified date January 2024
Source Changchun GeneScience Pharmaceutical Co., Ltd.
Contact Fanny Hou
Phone 8618502191682
Email fanny.hou@syneoshealth.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and to assess the safety and tolerability of multiple ascending doses of GS1-144 in healthy postmenopausal female participants in Part 2.


Description:

This study will be divided into two sequential parts: Part 1 single ascending dose (SAD), and Part 2 multiple ascending dose (MAD) with the overall design. Part 1 will enroll a total of approximately 38 healthy participants in five cohorts at 5 milligram (mg), 15 mg, 30 mg, 60 mg and 90 mg dose levels. Each cohort will have 2 participants receiving placebo. There is no restriction on the male-to female ratio. Part 2 will be conducted after confirming the safety and tolerability of the ->30mg dose in Part 1 and will enroll a total of approximately 30 healthy postmenopausal female participants and provisionally consists of three cohorts at 15 mg, 30 mg and 60 mg dose levels. Each cohort will have 2 participants receiving placebo.


Recruitment information / eligibility

Status Recruiting
Enrollment 68
Est. completion date December 17, 2024
Est. primary completion date December 17, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. At the time of signing the informed consent form (ICF): Part 1 only: healthy male and female participants aged between 18 and 45 years inclusive; Part 2 only: healthy women aged between 40 and 65 years inclusive who have undergone natural menopause; 2. Body weight >=50 kilogram (kg) (male), >=45 kg (female) with a body mass index between 18.0 and 32.0 kilogram per square meter (kg/m^2) inclusive at screening; 3. Part 1 only: Female participants are eligible to participate if they are not pregnant, not breastfeeding, and highly effective contraception includes placement of an intrauterine device or intrauterine system plus use of a condom; 4. Part 1 only: Male participants must agree to practice true abstinence; be surgically sterilized; or agree to use a condom plus effective contraception for their female partner, if of childbearing potential, from screening and for at least 90 days after dosing and refrain from donating sperm during this period. These contraception requirements do not apply if the male participant is in an exclusively same sex relationship; 5. Able to comprehend the nature of the study and any risks associated with participation and willing to cooperate and comply with protocol restrictions and requirements. Exclusion Criteria: 1. Any known allergy to the components or analogues of the investigational product, or those with an allergic constitution; 2. A history of currently suffering from any other cardiovascular, gastrointestinal, endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal and/or other major diseases deemed clinically significant by the investigator; 3. Known/confirmed history of malignancy; 4. A history of epileptic seizure or increased risk of epileptic seizure, or participants with a recent history of head trauma leading to loss of consciousness or concussion; 5. A history of currently suffering from hypothalamic dysfunction; 6. Significant acute/chronic infections within two weeks prior to dosing; 7. Undergone major surgical procedures within six months prior to screening or plan to undergo any surgery during the trial; 8. Participated in other clinical trials within 1 month prior to dosing; 9. Have lost or donated more than 400 mL of blood within 1 month prior to screening; 10. Have taken any prescription/over-the-counter drugs or dietary supplements within 7 days prior to dosing or within 5 halflives of the drug; 11. Clinically significant abnormalities on physical examination or genitourinary ultrasound at the time of screening; 12. Clinically significant abnormalities in vital signs; 13. Prolonged QTcF interval in 12-lead ECG results ; 14. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), blood creatinine (CRE), blood urea nitrogen (BUN), or international normalized ratio (INR) higher than the upper limit of normal (ULN) at screening, that are considered as clinically significant abnormalities by the investigator; 15. Part 2 only: abnormal sex hormone levels at screening that are considered clinically significant by the investigator; 16. Clinically significant abnormalities in thyroid function, parathyroid function, and neck ultrasound results at screening; 17. Women with positive pregnancy test result or those who are breastfeeding before dosing; 18. Positive hepatitis C virus antibody (HCV Ab), positive human immunodeficiency virus antibody (HIV Ab) or positive hepatitis B surface antigen (HbsAg) result at screening; 19. Unable to refrain from consuming grapefruit, pomelo, grapefruit juice, or pomelo juice from 48 hours prior to check-in until the end of the study; 20. Unable to refrain from consuming any foods or beverages containing caffeine or xanthine from 48 hours prior to check-in until the end of the study; 21. Unable to abstain from smoking/using tobacco products from 48 hours prior to check-in until the end of the study; 22. Unable to refrain from consuming alcohol from 48 hours prior to check-in until the end of the study; 23. Any history of narcotic use or drug abuse; 24. Any medical or other condition may affect the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GS1-144
Oral tablets.
Placebo
Matching placebo tablets.

Locations

Country Name City State
Australia Linear Clinical Research Perth Western Australia

Sponsors (2)

Lead Sponsor Collaborator
Changchun GeneScience Pharmaceutical Co., Ltd. Syneos Health

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Number of participants with TEAEs and SAEs will be reported. Up to Day 4
Primary Part 2:Number of Participants With TEAEs and SAEs Number of female post-menopausal participants with TEAEs and SAEs will be reported. Up to Day 12
Secondary Parts 1 and 2: AUC0-t- Area Under the Drug Concentration-time Curve From Time 0 to the Last Sample Collection Time t for GS1-144 AUC0-t will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Parts 1 and 2: AUC0-infinity- Area Under the Drug Concentration-time Curve From 0 to Infinity for GS1-144 AUC0-infinity will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Parts 1 and 2: Cmax- Maximum Observed Plasma Concentration for GS1-144 Cmax will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Parts 1 and 2: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for GS1-144 Tmax will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Parts 1 and 2: T1/2- Terminal Half-life for GS1-144 T1/2 will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Parts 1 and 2: CL/F- Apparent Clearance for GS1-144 CL/F will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Parts 1 and 2: Vd/F- Apparent Volume of Distribution for GS1-144 Vd/F will be assessed and reported. Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: Cmax,ss- Observed Maximum Concentration at Steady State for GS1-144 Cmax at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: Cmin,ss- Observed Minimum Concentration at Steady State for GS1-144 Cmin at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: Tmax,ss- Time of Cmax at Steady State for GS1-144 Tmax at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: Cavg,ss- Average Concentration at Steady State for GS1-144 Cavg at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: AUC0-t- Area Under the Drug Concentration-time Curve During the Dosing Interval at Steady State for GS1-144 AUC0-T at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: CLss/F- CL for Bioavailability at Steady State for GS1-144 CL/F at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2: T1/2,ss- Terminal Half-life at Steady State for GS1-144 T1/2 at steady state will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Secondary Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose Accumulation Ratio will be assessed and reported. Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
See also
  Status Clinical Trial Phase
Completed NCT04090957 - Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Phase 3
Completed NCT01052454 - Mindfulness-Based Stress Reduction for Hot Flashes Phase 0
Completed NCT00535288 - Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) Phase 3
Recruiting NCT00906308 - A Study of MF101 in Postmenopausal Women Phase 3
Completed NCT01452373 - Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women Phase 3
Completed NCT00560833 - Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012) Phase 3
Completed NCT05033886 - A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause Phase 3
Completed NCT05083884 - A Survey About Hot Flashes in Women Going Through the Menopause
Completed NCT01178892 - MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation N/A
Completed NCT00397176 - Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women Phase 1
Recruiting NCT06122181 - Study of HS-10384 in Participants of Chinese Postmenopausal Women Phase 1
Not yet recruiting NCT06393673 - A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women Phase 2
Withdrawn NCT02202707 - Vasomotor Symptoms and Cardiovascular Control N/A
Completed NCT00356447 - Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. Phase 3
Completed NCT05312567 - FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms Phase 2
Terminated NCT01353963 - Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients Phase 4
Completed NCT00446199 - Low-dose Hormone Therapy for Relief of Vasomotor Symptoms Phase 3
Completed NCT05850338 - Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom Control and Quality of Life in Postmenopausal Women N/A
Completed NCT02803268 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms Phase 1
Completed NCT00683800 - Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women Phase 3